曲妥珠单抗致HER2阳性乳腺癌患者心脏毒性的研究进展  

Progress in the study of trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients

作　　者：程跃启 王斐[1] 于理想[1] 郑超 余之刚[1] CHENG Yueqi;WANG Fei;YU Lixiang;ZHENG Chao;YU Zhigang(Breast Disease Diagnosis and Treatment Center,The Second Hospital of Shandong University,Jinan 250033,Shandong,China)

机构地区：[1]山东大学第二医院乳腺疾病诊疗中心,山东济南250033

出　　处：《山东大学学报(医学版)》2025年第1期17-24,共8页Journal of Shandong University:Health Sciences

基　　金：国家自然科学基金(82072914)。

摘　　要：曲妥珠单抗是一种靶向人表皮生长因子受体2(human epidermal growth factor receptor 2, HER2)的人源化单克隆抗体,在HER2阳性乳腺癌的临床治疗中表现出显著效果,但其临床应用可能引发左室射血分数降低、充血性心力衰竭及心律失常等心脏毒性问题。本文旨在综述当前关于曲妥珠单抗治疗HER2阳性乳腺癌诱导心脏毒性发生的相关研究进展,以及如何监测和预防相关心脏毒性的发生,以期为未来基础研究方向选择及临床优化曲妥珠单抗用药管理策略提供依据。Trastuzumab is a humanised monoclonal antibody that targets the human epidermal growth factor receptor 2(HER2)and has shown significant efficacy in the clinical treatment of HER2-positive breast cancer.However,its clinical use may lead to cardiotoxicity issues such as reduction in left ventricular ejection fraction(LVEF),congestive heart failure(CHF)and arrhythmias.The aim of this article is to review current research on trastuzumab-induced cardiotoxicity in the treatment of HER2-positive breast cancer and strategies for monitoring and preventing cardiotoxicity.The aim is to provide a basis for selecting future directions in basic research and optimising clinical management strategies for the use of trastuzumab.

关 键 词：乳腺癌 人表皮生长因子受体2 曲妥珠单抗 心脏毒性 危险因素 

分 类 号：R541[医药卫生—心血管疾病] R737.9[医药卫生—内科学] R992[医药卫生—临床医学]